Tarsus Pharmaceuticals Common Stock Net 2020-2024 | TARS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Tarsus Pharmaceuticals common stock net from 2020 to 2024. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Tarsus Pharmaceuticals common stock net from 2020 to 2024. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$173B
Vertex Pharmaceuticals (VRTX)	$129.2B
Bristol Myers Squibb (BMY)	$121.3B
Gilead Sciences (GILD)	$120.8B
CSL (CSLLY)	$91.5B
Regeneron Pharmaceuticals (REGN)	$90.7B
GSK (GSK)	$75.3B
Alnylam Pharmaceuticals (ALNY)	$36.1B
Argenex SE (ARGX)	$35.2B
BioNTech SE (BNTX)	$26.1B
Biogen (BIIB)	$25.1B
Illumina (ILMN)	$24B
BeiGene (BGNE)	$20B
Moderna (MRNA)	$16.5B
Incyte (INCY)	$15.7B
Genmab (GMAB)	$15.4B
Vaxcyte (PCVX)	$12.9B
Insmed (INSM)	$12.8B
BioMarin Pharmaceutical (BMRN)	$12.6B
Bio-Techne Corp (TECH)	$11.9B
Sarepta Therapeutics (SRPT)	$11.3B
Exelixis (EXEL)	$10.3B
Revolution Medicines (RVMD)	$10.2B
QIAGEN (QGEN)	$10.1B
Intra-Cellular Therapies (ITCI)	$9.7B
Exact Sciences (EXAS)	$9.5B
Bio-Rad Laboratories (BIO.B)	$9.4B
Roivant Sciences (ROIV)	$8.7B
Repligen (RGEN)	$7.8B
Ascendis Pharma (ASND)	$7.8B